Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Reuters

03 Aug 2026, 05:02 UTC · 2h ago

Obesity battle heats up again as Novo claws way back into race with Lilly

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Obesity battle heats up again as Novo claws way back into race with Lilly

Which stocks this story touches

How each ticker is affected

LLY+0.80
The company is described as having streaked ahead of its rival.
NVO-0.40
The company has faced profit warnings, leadership upheaval, and a sliding share price.

Read original · https://www.reuters.com/legal/litigation/obesity-battle-heats-up-again-novo-claws-way-back-into-race-with-lilly-2026-08-03/

Free · No account

Track these names every morning.

Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.

We’ll watch

$LLY$NVO#glp_1#healthcare#pharmaceuticals#profit_warning

Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.

Free forever · one email a day, max · unsubscribe in one click.How it works

How the impact breaks down

Where the story's weight lands

Impact by category

6 related stories

The Motley Fool
19h ago
Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
- healthcare
- pharmaceuticals
- weight loss drugs
Read

Obesity battle heats up ag… — LLY +0.80 | NewsImpactScreener

Obesity battle heats up again as Novo claws way back into race with Lilly

How each ticker is affected

Track these names every morning.

Impact by category

Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Obesity battle heats up again as Novo claws way back into race with Lilly

How each ticker is affected

Track these names every morning.

Impact by category

Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Biggest drivers

Most positively impacted

Most negatively impacted

AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

An IQVIA Insider Just Sold Over $1 Million in Stock. Here's What Long-Term Investors Should Know

AstraZeneca holds talks with Bristol Myers Squibb on potential megadeal, FT reports

1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree.

Obesity battle heats up again as Novo claws way back into race with Lilly

How each ticker is affected

Track these names every morning.

Impact by category

Next reads from the same story arc

Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Obesity battle heats up again as Novo claws way back into race with Lilly

How each ticker is affected

Track these names every morning.

Impact by category

Next reads from the same story arc

Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Biggest drivers

Most positively impacted

Most negatively impacted

AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

An IQVIA Insider Just Sold Over $1 Million in Stock. Here's What Long-Term Investors Should Know

AstraZeneca holds talks with Bristol Myers Squibb on potential megadeal, FT reports

1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree.